Mechanisms of immune dysfunction in stem cell transplantation

International Journal of Immunopharmacology

Volumn 22, Issue 12, 2000, Pages 1041-1056

  Talmadge, James E ^a   Singh, Rakesh ^a   Ino, Kazuhiko ^b   Ageitos, Ana ^c   Buyukberber, Suleyman ^d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^d INONU UNIVERSITY   (Turkey)

Author keywords

Immune regulation; Peripheral tolerance; T cell function

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; FAS ANTIGEN; LIGAND; PHYTOHEMAGGLUTININ;

APOPTOSIS; ARTICLE; AUTOGRAFT; BREAST CARCINOMA; CELL ACTIVATION; CELL FUNCTION; CELL LOSS; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOREGULATION; LIGAND BINDING; MAJOR CLINICAL STUDY; MITOGENESIS; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

ANTIGENS, CD14; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CD4-CD8 RATIO; CYTOKINES; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MEMBRANE GLYCOPROTEINS; MONOCYTES; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 0034537473     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(00)00078-3     Document Type: Article

References (98)

1. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation
2. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease
3. Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: A retrospective comparison with autologous bone marrow transplantation
4. Is blood or bone marrow better?
5. The evolution of clinical peripheral blood stem cell transplantation
6. The biology and clinical uses of blood stem cells
7. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation for metastatic breast cancer: Immunologic consequences affecting clinical outcome
8. Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer
9. Increased apoptosis of peripheral blood T cells following allogeneic hematopoietic cell transplantation
10. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults
11. Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire
12. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow
13. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation
14. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants
15. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation
16. Autologous peripheral blood stem cell transplantation: Analysis of autografted cells and lymphocyte recovery
17. Immunological reconstitution after high dose chemotherapy and autologous blood stem cell transplantation for advanced ovarian cancer
18. Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support
19. Immune reconstitution after bone marrow transplantation for combined immunodeficiencies: Down-modulation of Bcl-2 and high expression of CD95/Fas account for increased susceptibility to spontaneous and activation-induced lymphocyte cell death
20. + cells in granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood mononuclear cells induce secretion of interleukin-6 and G-CSF by marrow stroma
21. + cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells
22. Reversal of in vitro T cell clonal anergy by IL-2 stimulation
23. Differential induction of prostaglandin E2-dependent and -independent immune suppressor cells by tumor-derived GM-CSF and M-CSF
24. Phenotypic analysis of nylon-wool-adherent suppressor cells that inhibit the effector process of tumour cell lysis by lymphokine-activated killer cells in patients with advanced gastric carcinoma
25. Contribution of monocytes to the decreased lymphoproliferative response to phytohemagglutinin in patients with lung cancer
26. Comparison of monocyte dependent T cell inhibitory activity in GM-CSF vs. G-CSF mobilized PSC products
27. Monocytes from mobilized stem cells inhibit T cell function
28. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: A mechanism for monocyte-mediated suppression of T-cell proliferation
29. Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells
30. Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas
31. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
32. Fas-FasL-mediated CD4+ T-cell apoptosis following stem cell
33. Monocyte activation by an oral immunomodulator (bestatin) in lymphoma patients following autologous bone marrow transplantation
34. Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products
35. Autocrine T-cell suicide mediated by APO-I/(Fas/CD95)
36. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation induced apoptosis in T cell hybridomas
37. Fas (CD95)/FasL interactions required for programmed cell death after T cell activation
38. + T cells responding to bacterial superantigens
39. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor
40. Regulation of apoptosis in the immune system
41. Regulation of apoptosis and T cell activation by Fas-specific mAb
42. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
43. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediated apoptosis of uninfected T lymphocytes
44. Monocytes are required to prime peripheral blood T cells to undergo apoptosis
45. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions
46. Immune reconstitution following T-cell depleted bone marrow transplantation: Effect of age and posttransplant graft rejection prophylaxis
47. Human TH1 and TH2 subsets: Regulation of differentiation and role in protection and immunopathology
48. Human TH1 and TH2 subsets: Doubt no more
49. Lymphocyte responses and cytokines
50. Type 1 T helper and type 2 T helper cells: Functions, regulation and role in protection and disease
51. Regulation of cytokine gene expression in T helper cell subsets
52. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity
53. Local expression of antiinflammatory cytokines in cancer
54. Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma
55. Secretory products of macrophages
56. + T cells and monocytes from growth factor-mobilized peripheral blood stem cell products: A mechanism of immune dysfunction
57. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation
58. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells
59. Haemopoietic reconstitution after autologous blood stem cell transplantation in patients with malignancies: A multicenter retrospective study
60. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood
61. Induction of nonspecific suppressor cells in normal Lewis rats by a novel azaspirane, SK & F 105685
62. High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft
63. Single-step method for RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
64. Apoptosis parallels lymphopoiesis in bone marrow transplantation and HIV disease
65. Lymphopoiesis, apoptosis and immune amnesia
66. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus infected asymptomatic individuals
67. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study
68. High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children
69. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals
70. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes
71. Expression of interleukin-10 in isolated CD8+ T cells and monocytes from growth factor-mobilized peripheral blood stem cell products: A mechanism of immune dysfunction
72. Human monocytic cells contain high levels of intracellular Fas ligand. Rapid release following cellular activation
73. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: Impact on blood progenitor cell transplantation
74. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward Type-2 cytokine production and reduces severity of experimental graft-versus-host disease
75. Serum of healthy donors receiving granulocyte colony-stimulating factor induces T cell unresponsiveness
76. Inhibition of lymphocyte blastogenic response in healthy donors treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF): Possible role of lactoferrin and interleukin-1 receptor antagonist
77. Immune reconstitution following allogeneic peripheral blood stem cell transplant
78. Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2
79. Lymphokine profile in bone marrow transplant recipients
80. Constitutive and mitogen-stimulated cytokine mRNA expression by peripheral blood mononuclear cells from most autologous and allogeneic bone marrow transplant recipients is intact
81. Time course of interferon-g production deficiency after autologous and allogeneic stem cell transplantation for malignancies
82. T cell ontogeny after autologous bone marrow tranplantation: Failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4+ and CD8+ cells even in the presence of exogenous IL-2
83. High spontaneous IL-10 production in unrelated bone marrow transplant recipients is associated with fewer transplant-related complications and early deaths
84. Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression
85. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer
86. Serum levels of helper factors (IL-1 alpha, IL-1 beta and IL-6), T-cell products (sCD4 and sCD8), sIL-2R and beta 2-microglobulin in patients with B-CLL and benign B lymphocytosis
87. Granulocyte colony stimulating factor (G-CSF), macrophage-CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts
88. Decreased endogenous circulating steel factor (SLF) levels following allogeneic and autologous BMT: Lack of an inverse correlation with post-BMT myeloid engraftment
89. Serum concentrations of G-CSF during high-dose chemotherapy with autologous stem cell rescue
90. Increased serum levels of granulocyte colony-stimulating factor after autologous bone marrow or blood stem cell transplantation
91. Soluble CD4, soluble CD8, soluble CD25, lymphopoietic recovery, and endogenous cytokines after high-dose chemotherapy and blood stem cell transplantation
92. Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution
93. Autologous stem cell transplantation: Release of early and late acting growth factors relates with hematopoietic ablation and recovery
94. Cytokine production by peripheral blood monocytes and T cells during haemopoietic recovery after intensive chemotherapy
95. Accessory cells do not contribute to G-CSF or IL-6 production nor to rapid haematological recovery following peripheral blood stem cell transplantation
96. Autologous stem cell transplantation: Sequential production of hematopoietic cytokines underlying granulocyte recover
97. Lack of IL-2 cytokine expression despite Il-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: Selective expression of early activation markers
98. Translational control of interleukin 2 messenger RNA as a molecular mechanism of T cell energy